See the published version of this preprint at BMC Ophthalmology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Kei Shinoda
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1543-9345
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To evaluate the retinal function before and soon after an intravitreal injection of an anti-vascular endothelial growth factor (anti-VEGF) agents. Methods: Seventy-nine eyes of 79 patients that were treated by an intravitreal injection of an anti-VEGF agent for age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO) with macular edema (ME) were studied. The RETeval® system was used to record 28 Hz flicker electroretinograms (ERGs) from the injected and non-injected eyes before (Phase 1, P1), within 2 hours after the injection (P2), and 2 to 24 hours after the injection (P3). Patients were grouped by disease or by the injected agent and compared. The significance of the changes in the implicit times and amplitudes was determined by t tests. Results: The amplitudes were not significantly different at the three phases. The implicit time of the injected eye was 31.2±3.2 msec at P1, and it was not significantly different at P2 (31.7±3.1 msec) but it was significantly longer at P3 (32.2±3.3 msec, P<0.01, ANOVA for both). The implicit time in the non-injected fellow eye was 30.5±3.3 msec at P1, and it was significantly longer at P2 (31.1±3.2 msec) and phase 3 (31.3±3.4 msec, P<0.01, ANOVA for both). Conclusions: The results indicate that an intravitreal anti-VEGF injection will increase the implicit times not only in the injected eye but also in the non-injected eye soon after the intravitreal injection.
Keywords
aflibercept, age-related macular degeneration, electroretinogram, intravitreal injection, macular edema, ranibizumab, retinal vein occlusion, vascular endothelial growth factor
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Ophthalmology.
Version 3
Posted 16 May, 2019
No community comments so far
Editorial decision: Accept
On 19 May, 2019
Submission checks complete
On 09 May, 2019
Editor invited
On 09 May, 2019
Editor assigned
On 09 May, 2019
No comments provided
Editorial decision: Minor revision
On 03 May, 2019
Editor invited
On 03 Apr, 2019
Editor assigned
On 03 Apr, 2019
Submission checks complete
On 14 Jan, 2019
No comments provided
Editorial decision: Major revision
On 27 Feb, 2019
Review #2 received
Received 24 Feb, 2019
Review #1 received
Received 20 Feb, 2019
Reviewer #2 agreed
On 12 Feb, 2019
Reviewer #1 agreed
On 05 Feb, 2019
Reviewers invited
Invitations sent on 04 Feb, 2019
Editor assigned
On 19 Jan, 2019
Submission checks complete
On 14 Jan, 2019
Editor invited
On 14 Jan, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine Specialties
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Ophthalmology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Kei Shinoda
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1543-9345
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Ophthalmology.
Version 3
Posted 16 May, 2019
No community comments so far
Editorial decision: Accept
On 19 May, 2019
Submission checks complete
On 09 May, 2019
Editor invited
On 09 May, 2019
Editor assigned
On 09 May, 2019
No comments provided
Editorial decision: Minor revision
On 03 May, 2019
Editor invited
On 03 Apr, 2019
Editor assigned
On 03 Apr, 2019
Submission checks complete
On 14 Jan, 2019
No comments provided
Editorial decision: Major revision
On 27 Feb, 2019
Review #2 received
Received 24 Feb, 2019
Review #1 received
Received 20 Feb, 2019
Reviewer #2 agreed
On 12 Feb, 2019
Reviewer #1 agreed
On 05 Feb, 2019
Reviewers invited
Invitations sent on 04 Feb, 2019
Editor assigned
On 19 Jan, 2019
Submission checks complete
On 14 Jan, 2019
Editor invited
On 14 Jan, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine Specialties
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Ophthalmology.
Background: To evaluate the retinal function before and soon after an intravitreal injection of an anti-vascular endothelial growth factor (anti-VEGF) agents. Methods: Seventy-nine eyes of 79 patients that were treated by an intravitreal injection of an anti-VEGF agent for age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO) with macular edema (ME) were studied. The RETeval® system was used to record 28 Hz flicker electroretinograms (ERGs) from the injected and non-injected eyes before (Phase 1, P1), within 2 hours after the injection (P2), and 2 to 24 hours after the injection (P3). Patients were grouped by disease or by the injected agent and compared. The significance of the changes in the implicit times and amplitudes was determined by t tests. Results: The amplitudes were not significantly different at the three phases. The implicit time of the injected eye was 31.2±3.2 msec at P1, and it was not significantly different at P2 (31.7±3.1 msec) but it was significantly longer at P3 (32.2±3.3 msec, P<0.01, ANOVA for both). The implicit time in the non-injected fellow eye was 30.5±3.3 msec at P1, and it was significantly longer at P2 (31.1±3.2 msec) and phase 3 (31.3±3.4 msec, P<0.01, ANOVA for both). Conclusions: The results indicate that an intravitreal anti-VEGF injection will increase the implicit times not only in the injected eye but also in the non-injected eye soon after the intravitreal injection.
Figure 1
Figure 2
Figure 3
Loading...